Le Lézard
Classified in: Health, Science and technology
Subject: PDT


CMI Media Group Partnership Demonstrates the Effectiveness of Social to Drive Script Lift Among Key HCP Audiences

NEWARK, N.J., April 16, 2024 /PRNewswire/ -- PulsePoint, a technology company revolutionizing health decision-making, announced the availability of new social capabilities to engage and measure authenticated healthcare professionals (HCPs) during brand-relevant moments on Meta ? the parent company of Facebook and Instagram. By integrating HCP Social within programmatic omnichannel campaign strategies, marketers can improve engagement with HCPs during both free time and work time.

While brands have been able to run direct social media campaigns targeting HCPs in the past, PulsePoint's new HCP Social solution offers the additional benefits of authenticated NPI targeting, omnichannel activation, and measurement available directly in the PulsePoint platform. Using campaign physician-level data (PLD) provided by PulsePoint, the CMI Media Group team was able to demonstrate that the Meta/Facebook campaign drives reach and engagement across key HCP audiences. 

Over the last three years, PulsePoint and CMI Media Group have established a robust strategic partnership. As a result, these teams were able to evaluate the impact of this solution on HCP engagement and prescribing behavior for a leading brand treating Pseudobulbar Affect (PBA), a condition often misdiagnosed due to lack of awareness among physicians. After leveraging social media as part of an omnichannel engagement strategy to promote the brand's condition education content, and utilizing PulsePoint's advanced targeting and measurement tools, the campaign clickthrough rate (CTR) improved, and of the NPIs that clicked and prescribed, 8% were new brand prescribers (NBRx).

Walter Schmidli, VP, Paid Social at CMI Media Group, lauded the collaboration, stating, "HCP-specific insights for traditional social platforms have been historically limited, and we are excited to gain a deeper understanding of the channel's role in an HCP's journey through this partnership with PulsePoint."

CMI Media Group's 2023 Media Vitals survey reported that 70% of HCPs are active on social media monthly, with 43% reporting daily usage, making social media an attractive engagement opportunity for HCP marketers to reach relevant audiences within the vast addressable social universe. Social also reaches HCPs in moments outside of work, when they are open to engaging in brand awareness and educational messaging.

Andrew Stark, Chief Commercial Officer at PulsePoint, emphasized the strategic benefits of integrating social channels as a key component of an omnichannel approach, stating, "Our solution breaks down the barriers that traditionally arise from planning and executing social media budgets separately from other addressable channels. With our data foundation and insights around HCP behaviors, brands can target the most relevant HCP audiences with precision and measure the impact of their campaigns in driving real-world outcomes."

Additional social channels are being integrated onto the PulsePoint platform in the coming months.

About PulsePoint

PulsePoint is a leading technology company that uses real-world data in real-time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and consumer populations with an unprecedented level of accuracy?delivering unparalleled results to the clients we serve. The company is now a part of Internet Brands. For more information, visit pulsepoint.com.

Contact: Sanwari Gupta, [email protected]

SOURCE PulsePoint

These press releases may also interest you

at 17:25
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

at 16:10
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...

at 16:10
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...

News published on and distributed by: